Bicycle Therapeutics Plc (BCYC)
3.55
-0.09
(-2.47%)
USD |
NASDAQ |
Oct 23, 16:00
3.54
-0.01
(-0.28%)
After-Hours: 20:00
Bicycle Therapeutics Enterprise Value : -316.00M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | -316.00M |
| October 22, 2026 | -311.47M |
| October 21, 2026 | -315.00M |
| October 20, 2026 | -313.49M |
| October 19, 2026 | -316.76M |
| October 16, 2026 | -320.54M |
| October 15, 2026 | -313.49M |
| October 14, 2026 | -318.02M |
| October 13, 2026 | -311.97M |
| October 12, 2026 | -303.41M |
| October 09, 2026 | -298.88M |
| October 08, 2026 | -302.91M |
| October 07, 2026 | -306.94M |
| October 06, 2026 | -303.91M |
| October 05, 2026 | -292.83M |
| October 02, 2026 | -324.57M |
| October 01, 2026 | -315.50M |
| September 30, 2026 | -309.46M |
| September 29, 2026 | -310.97M |
| September 28, 2026 | -307.94M |
| September 25, 2026 | -309.20M |
| September 24, 2026 | -306.94M |
| September 23, 2026 | -313.49M |
| September 22, 2026 | -306.94M |
| September 21, 2026 | -311.97M |
| Date | Value |
|---|---|
| September 18, 2026 | -310.97M |
| September 17, 2026 | -309.46M |
| September 16, 2026 | -311.47M |
| September 15, 2026 | -309.96M |
| September 14, 2026 | -298.88M |
| September 11, 2026 | -300.39M |
| September 10, 2026 | -301.90M |
| September 09, 2026 | -293.08M |
| September 08, 2026 | -284.27M |
| September 04, 2026 | -278.22M |
| September 03, 2026 | -281.24M |
| September 02, 2026 | -278.22M |
| September 01, 2026 | -288.30M |
| August 31, 2026 | -286.79M |
| August 28, 2026 | -283.26M |
| August 27, 2026 | -276.71M |
| August 26, 2026 | -275.45M |
| August 25, 2026 | -273.69M |
| August 24, 2026 | -276.71M |
| August 21, 2026 | -274.70M |
| August 20, 2026 | -281.24M |
| August 19, 2026 | -286.28M |
| August 18, 2026 | -293.84M |
| August 17, 2026 | -293.34M |
| August 14, 2026 | -298.37M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Autolus Therapeutics Plc | 574.58M |
| DBV Technologies SA | 364.13M |
| Cellectis SA | 36.12M |
| Akari Therapeutics Plc | 7.336M |
| Biodexa Pharmaceuticals Plc | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -50.42M |
| Revenue (Quarterly) | 0.6301M |
| Total Expenses (Quarterly) | 51.05M |
| EPS Diluted (Quarterly) | -0.7224 |
| Gross Profit Margin (Quarterly) | -69.64% |
| Profit Margin (Quarterly) | -8.00K% |
| Earnings Yield | -76.94% |
| Normalized Earnings Yield | -76.94 |